Use of bezafibrate for treating diabetes

• US 5,304,575 A
• Filed: 12/17/1992
• Issued: 04/19/1994
• Est. Priority Date: 09/01/1987
• Status: Expired due to Fees

• Current Assignee: Boehringer Mannheim GmbH (Roche Holding AG)
• Original Assignee: Boehringer Mannheim GmbH (Roche Holding AG)
• Inventors: Beck, Walter
• Primary Examiner(s): GOLDBERG, JEROME D
• Application Number:
  US07/993,525
• Time in Patent Office: 488 Days
• Field of Search: 514/563, 514/592, 424/10
• US Class Current: 514/563
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Bezafibrate is used for the treatment of normolipidaemic diabetes mellitus type II.

Claims

1. A method for reducing the insulin level in normolipidaemic patients suffering from diabetes mellitus type II, which method comprises orally administering to said patient an effective amount of bezafibrate.

2. A method according to claim 1, in which the bezafibrate is administered at a dosage of from 200 to 600 mg. per day.

3. A method for reducing the insulin level in normolipidaemic patients suffering from diabetes mellitus type II, which method comprises orally administering to said patient, in a single dosage unit, an effective amount of bezafibrate and an effective amount of a sulphonylurea.